SULFOSE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sulfose, and when can generic versions of Sulfose launch?
Sulfose is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in SULFOSE is trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine). There is one drug master file entry for this compound. Additional details are available on the trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SULFOSE?
- What are the global sales for SULFOSE?
- What is Average Wholesale Price for SULFOSE?
Summary for SULFOSE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 4,151 |
| DailyMed Link: | SULFOSE at DailyMed |
US Patents and Regulatory Information for SULFOSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | SULFOSE | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) | SUSPENSION;ORAL | 080013-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Wyeth Ayerst | SULFOSE | trisulfapyrimidines (sulfadiazine;sulfamerazine;sulfamethazine) | TABLET;ORAL | 080013-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
